GCA
ATOS icon

Gallagher Capital Advisors’s Atossa Therapeutics ATOS Stock Holding History

Gallagher Capital Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,105
Closed -$27.5K – 68
2025
Q3 		$27.5K Buy
+2,105
New +$26K 0.02% 68
2025
Q2 		– Sell
-1,738
Closed -$17.5K – 61
2025
Q1 		$17.5K Hold
1,738
– – 0.01% 65
2024
Q4 		$24.6K Buy
+1,738
New +$33.9K 0.02% 65

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Gallagher Capital Advisors's ATOS Position: Q4 2025 in Review

Gallagher Capital Advisors sold out of Atossa Therapeutics (ATOS) in Q4 2025, closing a stake of 2,105 shares — an estimated $27.5K sold.

Gallagher Capital Advisors first reported a position in ATOS in Q4 2024 and held it in 3 quarters. The position peaked at $27.5K in Q3 2025. 67 funds tracked by Wall St. Rank hold ATOS as of Q4 2025.

  • Gallagher Capital Advisors reported no remaining Atossa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Gallagher Capital Advisors sold 2,105 Atossa Therapeutics shares in Q4 2025, an estimated $27.5K.
  • Gallagher Capital Advisors first reported a position in Atossa Therapeutics in Q4 2024 and held it in 3 quarters.
  • Gallagher Capital Advisors's Atossa Therapeutics position peaked at $27.5K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2025.

Based on Gallagher Capital Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.